# Chronic Kidney Disease (CKD) Management

## Staging by GFR
- **G1**: GFR ≥90 (normal/high) — with evidence of kidney damage
- **G2**: GFR 60-89 (mildly decreased)
- **G3a**: GFR 45-59 (mild-moderate decrease)
- **G3b**: GFR 30-44 (moderate-severe decrease)
- **G4**: GFR 15-29 (severely decreased)
- **G5**: GFR <15 (kidney failure)

## Albuminuria Categories
- **A1**: <30 mg/g (normal to mildly increased)
- **A2**: 30-300 mg/g (moderately increased — "microalbuminuria")
- **A3**: >300 mg/g (severely increased — "macroalbuminuria")

## Blood Pressure Management
- Target: <130/80 mmHg (for all CKD patients)
- **First-line**: ACEi or ARB if albuminuria (A2-A3) — reduce proteinuria and slow progression
- Do NOT combine ACEi + ARB (increased adverse events without benefit)
- Monitor K+ and creatinine 1-2 weeks after initiation or dose change (up to 30% rise in Cr acceptable)

## Kidney-Protective Therapies
- **SGLT2 inhibitors**: Dapagliflozin or empagliflozin — slow CKD progression, reduce proteinuria (indicated if eGFR ≥20)
- **Finerenone** (non-steroidal MRA): For T2DM with CKD — reduces kidney and cardiovascular events
- **GLP-1 receptor agonists**: Semaglutide, liraglutide — cardiovascular and possible renal benefit in T2DM

## Anemia of CKD
- Screen when eGFR <60: CBC, reticulocyte count, iron studies, B12/folate
- **Iron supplementation first**: Target TSAT >20%, ferritin >100 ng/mL (>200 for dialysis patients)
- **Erythropoiesis-stimulating agents (ESA)**: Epoetin alfa, darbepoetin — target Hgb 10-11.5 g/dL
- Avoid Hgb >13 g/dL (increased cardiovascular events)

## CKD-Mineral and Bone Disorder
- **Phosphorus**: Restrict dietary phosphorus, phosphate binders (sevelamer, calcium acetate, lanthanum) if serum phos elevated
- **Calcium**: Avoid calcium-based binders if hypercalcemia; monitor total and ionized calcium
- **Vitamin D**: Check 25-OH vitamin D; supplement if deficient; active vitamin D (calcitriol) for secondary hyperparathyroidism
- **PTH management**: Target varies by CKD stage; calcimimetics (cinacalcet) for dialysis patients with elevated PTH

## Metabolic Acidosis
- Maintain serum bicarbonate ≥22 mEq/L
- Oral sodium bicarbonate supplementation (may slow CKD progression)

## Nephrology Referral
- eGFR <30 (plan for dialysis access at eGFR 15-20)
- Rapid decline (>5 mL/min/1.73m²/year)
- Significant proteinuria (ACR >300)
- Uncertain etiology, refractory hypertension, refractory electrolyte abnormalities

## Dialysis Preparation (eGFR 15-20)
- Modality education: Hemodialysis vs peritoneal dialysis vs kidney transplant
- Vascular access creation: AV fistula preferred (6 months before anticipated start)
- Hepatitis B vaccination series
- Transplant evaluation if candidate
